Treatment of diabetic nephropathy: a rational approach based on its pathophysiology.
Tuttle
K R
KR
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7870.
DeFronzo
R A
RA
Stein
J H
JH
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000628:therapy*; D004044:Dietary Proteins / Q000008:administration & dosage; D005919:Glomerular Filtration Rate / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy*; D015431:Weight Loss
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004044:Dietary Proteins; D007328:Insulin